Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corporation entered into stock purchase agreements with Invenra Inc. and two of Invenra’s investors. Twist will issue up to 632,328 shares of common stock. Up to 324,558 shares plus $5 million in cash will be provided to Invenra in exchange for a license agreement and certain technology. Twist will also issue up to 307,770 shares to two Invenra investors in exchange for preferred stock, giving Twist approximately a 6% ownership stake in Invenra. Twist gains the right to designate one director to Invenra’s board, whose members, including the Twist designee, may approve two additional directors. The company simultaneously granted registration rights and is filing a prospectus supplement to register the resale of these shares.
Twist Bioscience chief financial officer Adam Laponis sold 7,000 shares of common stock in an open-market transaction at $50 per share on February 12, 2026. After this planned sale under a previously adopted Rule 10b5-1 trading plan, he directly holds 130,031 shares.
Patrick Finn has filed a notice of proposed sale of restricted securities, indicating an intent to sell 1,750 shares of common stock of TWST through Fidelity Brokerage Services LLC. The planned sale, listed for 02/13/2026 on NASDAQ, has an aggregate market value of 87572.02. Shares of the issuer outstanding were 61,311,704 at the time referenced.
The shares to be sold were recently acquired through option exercises dated 11/19/2018 and 10/24/2019 (settled on 02/13/2026) totaling 1,212 shares for cash, and 538 shares from restricted stock vesting on 11/05/2024 as compensation. Over the past three months, Finn has already sold multiple common stock blocks, including 23,279 shares for gross proceeds of 931160.00 on 01/13/2026 and 3,500 shares for 175789.05 on 02/12/2026.
Twist Bioscience Corp executive Dennis Cho reported an open-market sale of company stock. On February 11, 2026, he sold 5,000 shares of common stock at a price of $49.93 per share. After this transaction, he directly owned 138,581 shares.
The filing notes that this sale was carried out under a Rule 10b5-1 trading plan that Cho had previously adopted on May 7, 2025. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience, indicating the transaction involves a senior member of management.
Twist Bioscience received a notice that a holder plans to sell 2,184 shares of its common stock on or about 02/13/2026. The shares, with an aggregate market value of $105,401.37, will be sold through Fidelity Brokerage Services LLC on the NASDAQ exchange.
The securities were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation. As of the filing, there were 61,311,704 common shares outstanding, which is a baseline figure and not the amount being sold.
Patrick Finn filed a notice to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144. The filing lists an aggregate market value of 175,789.00 for these shares, to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The shares come from option grants dated 11/19/2018 and 10/24/2019 totaling 2,500 shares, and 1,000 shares from restricted stock vesting on 11/08/2024. Recent activity also shows separate sales, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Adam Laponis filed a Form 144 indicating an intent to sell up to 7,000 shares of Twist Bioscience common stock. The planned sale through Fidelity Brokerage Services on NASDAQ has an aggregate market value of 350000.00. Twist Bioscience had 61,311,704 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer on 10/01/2025, 10/08/2025, and 10/29/2025, totaling 6,, , , , , 614, 2,170, and 4,216 shares as compensation.
Twist Bioscience Corp chief accounting officer Robert F. Werner reported a charitable stock gift. On 02/09/2026, he disposed of 2,000 shares of Twist Bioscience common stock in a bona fide gift to a charitable organization at a reported price of $0 per share.
Following this gift transfer, Werner directly beneficially owned 56,738 shares of Twist Bioscience common stock.
A shareholder of TWST plans to sell 5,000 shares of common stock through Fidelity Brokerage Services for an aggregate market value of $249,650.00, with an approximate sale date of February 11, 2026 on the NASDAQ exchange.
The filing notes that 61,311,704 shares of this class were outstanding. It also lists recent sales by Dennis H. Cho, including 1,099 common shares sold on February 3, 2026 for gross proceeds of $51,186.47, alongside three earlier sales in November and December 2025.
Twist Bioscience director Keith Crandell received an annual equity award of 5,095 shares of common stock on February 5, 2026 at a price of $0 per share. After this grant, he directly owns 27,571 shares of Twist Bioscience common stock.
These annual award shares will fully vest on the earlier of the one-year anniversary of the grant date or the first annual shareholder meeting after the grant, as long as he continues serving as a non‑employee director. In addition, 76,047 shares are held indirectly through the Keith L. Crandell Trust, for which he and his spouse are co‑trustees and he is the sole beneficiary.